Takaoka, Japan

Chosaku Yoshida

This inventor holds 17 USPTO granted patents. Top assignee: Toyama Chemical Co., Ltd.. Active years: 1978-2000.


% Patents Active = 100.0

Average Co-Inventor Count = 9.3

ph-index = 9

Forward Citations = 225(Granted Patents)


Location History:

  • Takaoka, JA (1978)
  • Tokaoka, JP (1990)
  • Takaoka, JP (1978 - 2000)

Company Filing History:


Years Active: 1978-2000

Loading Chart...
17 patents (USPTO):Explore Patents

Title: Chosaku Yoshida: Innovator in Immunomodulation and Cell Adhesion Inhibition

Introduction

Chosaku Yoshida is a prominent inventor based in Takaoka, Japan. He has made significant contributions to the field of immunology and pharmacology, holding a total of 17 patents. His work focuses on developing innovative treatments for autoimmune diseases and related conditions.

Latest Patents

Yoshida's latest patents include groundbreaking inventions such as an immunomodulator and a cell adhesion inhibitor. These patents detail methods for treating autoimmune diseases through the use of a 4H-1-benzopyran-4-one compound. The compounds described in his patents are designed to effectively modulate immune responses and inhibit cell adhesion, providing new avenues for therapeutic intervention.

Career Highlights

Throughout his career, Chosaku Yoshida has been associated with Toyama Chemical Co., Ltd., where he has contributed to various research and development projects. His innovative approaches have positioned him as a key figure in the pharmaceutical industry, particularly in the realm of immunotherapy.

Collaborations

Yoshida has collaborated with notable colleagues, including Isamu Saikawa and Shuntaro Takano. These partnerships have fostered a collaborative environment that enhances the development of new therapeutic strategies.

Conclusion

Chosaku Yoshida's work exemplifies the spirit of innovation in the field of immunology. His contributions continue to pave the way for advancements in the treatment of autoimmune diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…